Evolent Health, Inc (NYSE:EVH) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Evolent Health, Inc (NYSE:EVH) have received a consensus rating of “Moderate Buy” from the fourteen research firms that are presently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and twelve have given a buy recommendation to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $9.50.

A number of analysts have weighed in on EVH shares. Citizens Jmp decreased their price objective on Evolent Health from $11.00 to $10.00 and set a “market outperform” rating for the company in a research report on Tuesday, January 6th. Oppenheimer cut their price target on Evolent Health from $18.00 to $12.00 and set an “outperform” rating for the company in a research note on Wednesday, November 12th. Citigroup lowered their price objective on shares of Evolent Health from $9.50 to $6.00 and set a “buy” rating on the stock in a research report on Friday, January 9th. Piper Sandler set a $6.00 price objective on shares of Evolent Health in a research note on Tuesday, December 2nd. Finally, BMO Capital Markets initiated coverage on shares of Evolent Health in a research note on Thursday, November 13th. They issued an “outperform” rating and a $7.00 target price for the company.

Evolent Health Price Performance

Shares of NYSE:EVH opened at $2.77 on Tuesday. Evolent Health has a one year low of $2.56 and a one year high of $12.06. The stock has a market capitalization of $308.57 million, a price-to-earnings ratio of -1.75 and a beta of 0.27. The company has a 50-day simple moving average of $3.57 and a 200-day simple moving average of $5.92. The company has a debt-to-equity ratio of 1.25, a quick ratio of 1.33 and a current ratio of 1.33.

Institutional Investors Weigh In On Evolent Health

A number of institutional investors have recently added to or reduced their stakes in EVH. Nisa Investment Advisors LLC increased its stake in Evolent Health by 88.0% in the 2nd quarter. Nisa Investment Advisors LLC now owns 2,551 shares of the technology company’s stock valued at $29,000 after purchasing an additional 1,194 shares in the last quarter. CIBC Private Wealth Group LLC grew its stake in Evolent Health by 4,000.0% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 4,100 shares of the technology company’s stock valued at $35,000 after acquiring an additional 4,000 shares during the last quarter. Strs Ohio purchased a new position in Evolent Health during the 1st quarter valued at about $47,000. Vise Technologies Inc. acquired a new position in Evolent Health during the fourth quarter worth about $50,000. Finally, Pilgrim Partners Asia Pte Ltd acquired a new position in Evolent Health during the third quarter worth about $51,000.

About Evolent Health

Evolent Health, Inc is a U.S.-based healthcare technology and services company that partners with health systems, physician organizations and health plans to design, build and operate value-based care programs. Headquartered in Arlington, Virginia, the company was founded in 2011 as a joint venture between TPG and the University of Pittsburgh Medical Center (UPMC). Evolent Health aims to help its clients transition from fee-for-service payment models to value-based care arrangements by leveraging its proprietary technology platforms and clinical expertise.

The company’s core offerings include care management solutions, population health analytics and clinical advisory services.